My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Context Therapeutics Inc.

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Chief Medical Officer Transition
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Upcoming Investor Conferences
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics to Participate in Upcoming Investor Conferences in November
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers BCAB CNTX
Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Announces $100 Million Private Placement
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
From Context Therapeutics Inc.
Via GlobeNewswire
Tickers CNTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.